Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF20513 with/without Booster in Mild AD or MCI
NCT03819699Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of Lu AF20513 in Alzheimer's disease (AD) (3 cohorts), sponsored by Lundbeck. Primary endpoints: Area Under the Curve, Maximum Concentration and 1 more. Started Dec 2018; status: terminated.
02
Drugs
Lu AF20513
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03819699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819699.